The “Molecular and Translational Medicine” Section publishes reviews and original peer-reviewed papers which aim to cover studies concerning disease pathogenesis at the molecular or physiological level, as well as basic preclinical, clinical, and translational aspects. We encourage scientists to submit their results that have the potential for application in human disease, as well as research obtained from clinical trials or animal models of human diseases that has the potential to shed light on the underlying causes of various human diseases and cancer, allowing for the development of future human medicines, medical devices, and diagnostics. In this context, we are pleased to feature some recently published papers on molecular and translational medicine in Biomedicines (ISSN: 2227-9059), which will provide valuable insights into this exciting field.

1. “Navigating Challenges and Opportunities in Multi-Omics Integration for Personalized Healthcare”
by Alex E. Mohr, Carmen P. Ortega-Santos, Corrie M. Whisner, Judith Klein-Seetharaman and Paniz Jasbi
Biomedicines 2024, 12(7), 1496; https://doi.org/10.3390/biomedicines12071496
Available online: https://www.mdpi.com/2227-9059/12/7/1496

2. “Transient Left Ventricular Dysfunction from Cardiomyopathies to Myocardial Viability: When and Why Cardiac Function Recovers”
by Giancarlo Trimarchi, Lucio Teresi, Roberto Licordari, Alessandro Pingitore, Fausto Pizzino, Patrizia Grimaldi, Danila Calabrò, Paolo Liotta, Antonio Micari, Cesare de Gregorio et al
Biomedicine. 2024, 12(5), 1051; https://doi.org/10.3390/biomedicines12051051
Available online: https://www.mdpi.com/2227-9059/12/5/1051

3. “Fibromyalgia: A Review of the Pathophysiological Mechanisms and Multidisciplinary Treatment Strategies”
by Lina Noelia Jurado-Priego, Cristina Cueto-Ureña, María Jesús Ramírez-Expósito and José Manuel Martínez-Martos
Biomedicines 2024, 12(7), 1543; https://doi.org/10.3390/biomedicines12071543
Available online: https://www.mdpi.com/2227-9059/12/7/1543

4. “Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions”
by Rajesh Jha, Sara Lopez-Trevino, Haritha R. Kankanamalage and Jay C. Jha
Biomedicines 2024, 12(5), 1098. https://doi.org/10.3390/biomedicines12051098
Available online: https://www.mdpi.com/2227-9059/12/5/1098

5. “Immunosuppression in Sepsis: Biomarkers and Specialized Pro-Resolving Mediators”
by Cristina M. Padovani and Kingsley Yin
Biomedicines 2024, 12(1), 175. https://doi.org/10.3390/biomedicines12010175
Available online: https://www.mdpi.com/2227-9059/12/1/175

6. “Osteoporosis, Osteoarthritis, and Subchondral Insufficiency Fracture: Recent Insights”
by Shunichi Yokota, Hotaka Ishizu, Takuji Miyazaki, Daisuke Takahashi, Norimasa Iwasaki and Tomohiro Shimizu
Biomedicines 2024, 12(4), 843; https://doi.org/10.3390/biomedicines12040843
Available online: https://www.mdpi.com/2227-9059/12/4/843

7. “Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline”
by Antonio Lardaro, Ludovica Quarta, Stefania Pagnotta, Giorgio Sodero, Sandro Mariani, Maria Del Ben, Giovambattista Desideri, Evaristo Ettorre and Francesco Baratta
Biomedicines 2024, 12(8),1750; https://doi.org/10.3390/biomedicines12081750
Available online: https://www.mdpi.com/2227-9059/12/8/1750

8. “Current Knowledge on the Use of Neuromonitoring in Thyroid Surgery”
by Beata Wojtczak, Karolina Sutkowska-Stępień, Mateusz Głód, Krzysztof Kaliszewski, Krzysztof Sutkowski and Marcin Barczyński
Biomedicines 2024, 12(3), 675; https://doi.org/10.3390/biomedicines12030675
Available online: https://www.mdpi.com/2227-9059/12/3/675

9. “Carriers of Heterozygous Loss-of-Function ACE Mutations Are at Risk for Alzheimer’s Disease”
by Sergei M. Danilov, Ivan A. Adzhubei, Alexander J. Kozuch, Pavel A. Petukhov, Isolda A. Popova, Ananyo Choudhury, Dhriti Sengupta and Steven M. Dudek
Biomedicines 2024, 12(1), 162; https://doi.org/10.3390/biomedicines12010162
Available online: https://www.mdpi.com/2227-9059/12/1/162

10. “Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?”
by Mohammad Jad Moussa, Matthew T. Campbell and Omar Alhalabi
Biomedicines 2024, 12(3), 519; https://doi.org/10.3390/biomedicines12030519
Available online: https://www.mdpi.com/2227-9059/12/3/519

To acknowledge the above authors’ excellent contributions, we are happy to provide a full waiver to each team of the above publications. We also would like to take this opportunity to thank all the research groups that have submitted to Biomedicines. We would appreciate it if you would circulate this document among your colleagues and network. Furthermore, the following opportunities for collaboration may be of interest to you:

Submitting a manuscript:
This Section is currently open for submissions. Papers may be submitted via the following link: https://www.mdpi.com/user/manuscripts/upload/?journal=biomedicines. 

Joining the Volunteer Reviewer Board:
If you are an active researcher in the field of biomedicinal research and are interested in joining the Volunteer Reviewer Board of Biomedicines, please do not hesitate to submit your application via the following link: https://susy.mdpi.com/volunteer/profile/edit. 

Biomedicines Editorial Office